Coronavirus: Immunotherapy

(asked on 24th May 2021) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government when treatments for immunocompromised groups, including monoclonal antibody therapies, will be available as an alternative to COVID-19 vaccines; and which groups will be able to access those treatments.


Answered by
Lord Bethell Portrait
Lord Bethell
This question was answered on 3rd June 2021

Immunocompromised individuals are a priority cohort for research into therapeutic and prophylaxis treatments such as monoclonal antibody therapies, novel antivirals and repurposed compounds.

A wide range of treatments in all three of these groups are currently in clinical trials in the United Kingdom and the Government is monitoring trials worldwide. It is not yet possible to determine the exact patient groups who may be able to benefit from these treatments, as this will depend on results released by the ongoing trials when they conclude, licensing approval from the Medicines and Healthcare products Regulatory Agency and deployment planning between the Department, NHS England and expert clinicians. The Government is taking steps to ensure supply of treatments in the event that they are found to be effective at treating COVID-19, including for immunocompromised individuals.

Reticulating Splines